Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma was successful. Nearly three months later, the magnitude of success for its Pomalyst (pomalidomide) successor is clear.

Currently available treatments for chronic hepatitis D virus (HDV) infection rarely result in a cure after a defined treatment period. Researchers from Aligos Therapeutics Inc. hypothesized that antisense oligonucleotides (ASOs) targeting HDV RNAs may inhibit intracellular HDV RNA amplification.

Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a genetic liver disorder caused by mutations in the ABCB4 gene encoding multidrug resistance protein 3 (MCP3) in humans, a biliary phospholipid transporter. Rectify Pharmaceuticals Inc. has developed the novel compound RTY-694, a dual-acting MDR3/BSEP positive modulator that increased the protein function of both MDR3 and BSEP.

Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.

Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.

Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics.

GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.

At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease affecting 1.5 billion people worldwide, this momentum is strongly reflected at the ongoing European Association for the Study of the Liver 2026 congress in Barcelona. The mandate positions liver disease alongside cancer, cardiovascular disease and diabetes as a core global health priority.

X-linked Alport syndrome is an inherited kidney disease caused by pathogenic mutations in the COL4A5 gene. Patients develop hematuria, proteinuria and kidney function decline leading to end-stage renal disease. Nionyx Bio Inc. has developed ONYX-101, a novel kidney-targeting therapeutic designed to ensure durable COL4A5 restoration through dual-vector AAV delivery using NYX capsids that were optimized for kidney targeting.